References
- U.S. Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. http://www.surgeongeneral.gov/library/reports/50-years-of-progress/full-report.pdf. Accessed June 10, 2015. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health 2014
- National Institute for Health and Welfare. Tobacco statistics 2012. http://www.julkari.fi/bitstream/handle/10024/110551/Tr27_13.pdf?sequence =4. Accessed January 19, 2015. Helsinki: THL 2013
- Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence: 2008 Update. Clinical Practice Guideline. http://www.ncbi.nlm.nih.gov/books/NBK63952/. Accessed 26, March 2015. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service 2008
- Getsios D, Marton JP, Revankar N, et al. Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventions. PharmacoEconomics 2013;31:767-80
- Mills EJ, Wu P, Lockhart I, et al. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med 2012;44:588-97
- Cahill K, Stevens S, Perera R, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013;5
- Linden K, Jormanainen V, Linna M, et al. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. Cur Med Res Opin 2010;26:549-60
- Zimovetz EA, Wilson K, Samuel M, et al. A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities. J Ev Clin Pract 2011;17:288-97
- Annemans L, Marbaix S, Nackaerts K, et al. Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation. Prev Med Reports 2015;2:189-95
- Howard P, Knight C, Boler A, et al. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US Adult Smokers. PharmacoEconomics 2008;26:497-511
- Statistics Finland. Population by age (1-v), gender and area 1980–2013. http://193.166.171.75/Dialog/varval.asp?ma=050_vaerak_tau_104&ti=V%E4est%F6+i%E4n+%281%2Dv%2E%29+ja+sukupuolen+mukaan+alueittain+1980+%2D+2013&path=./Database/StatFin/vrm/vaerak/&lang=3&multilang=fi. Accessed January 19, 2015
- Borodulin K, Levälahti E, Saarikoski L, et al. Kansallinen FINRISKI 2012 –terveystutkimus. Osa 2: tutkimuksen taulukkoliite. http://www.julkari.fi/bitstream/handle/10024/110912/URN_ISBN_978-952-302-053-5.pdf?sequence=. Accessed January 9, 2015. Helsinki: THL 2014
- Helldán A, Helakorpi S, Virtanen S, et al. Health behaviour and health among the Finnish Adult Population, Spring 2013. http://www.julkari.fi/bitstream/handle/10024/110841/URN_ISBN_978-952-302-051-1.pdf?sequence =1. Accessed January 19, 2015. Helsinki: THL 2013
- Koskinen S, Lundqvist A, Ristiluoma N, eds. Health, functional capacity and welfare in Finland in 2011. http://www.julkari.fi/bitstream/handle/10024/90832/Rap068_2012_netti.pdf?sequence=1. Accessed February 2, 2015. Helsinki: THL 2012
- Hind D, Tappenden P, Peters J, et al. Varenicline in the management of smoking cessation: a single technology appraisal. Health Technol Assess 2009;13(2 Suppl)
- Annemans L, Nackaerts K, Bartsch P, et al. Cost-effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. Clin Drug Investiq 2009;29:655-65
- Mannino DM, Buist AS, Petty TL, et al. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003;58:388-93
- Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. PharmacoEconomics 2005;23:619-37
- Trippoli S, Vaiani M, Lucioni C, et al. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. PharmacoEconomics. 2001;19:855-63
- Hay JW, Sterling KL. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease. PharmacoEconomics 2005;23:133-41
- Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 1998;29:1083-91
- Duncan PW, Lai SM, Keighley J. Defining post-stroke recovery: implications for design and interpretation of drug trials. Neuropharmacol 2000;39:835-41
- Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. PharmacoEconomics 2003;21:191-200
- Szende A, Svensson K, Stahl E, et al. Psychometric and utilitybased measures of health status of asthmatic patients with different disease control level. PharmacoEconomics 2004;22:537-47
- Wetter DW, Cofta-Gunn L, Fouladi RT, et al. Late relapse/sustained abstinence among former smokers: a longitudinal study. Prev Med 2004;39:1156-63
- Krall EA, Garvey AJ, Garcia RI. Smoking relapse after 2 years of abstinence: findings from the VA Normative Aging Study. Nicotine Tob Res 2002;4:95-100
- Gonzales D, Hajek P, Pliamm L, et al. Retreatment With Varenicline for Smoking Cessation in Smokers Who Have Previously Taken Varenicline: A Randomized, Placebo-Controlled Trial. Clin PharmTher. 2014;96:390-396.
- Reda AA, Kotz D, Evers SMAA, et al. Healthcare financing systems for increasing the use of tobacco dependence treatment (Review). The Cochrane Collaboration 2012;Issue 6
- Tiihonen J, Ronkainen K, Kangasharju A, et al. The net effect of smoking on healthcare and welfare costs. A cohort study. BMJ Open 2012;2:e001678
- Kapiainen S, Väisänen A, Haula T. Terveyden- ja sosiaalihuollon yksikkökustannukset Suomessa vuonna 2011. https://www.julkari.fi/bitstream/handle/10024/114683/THL_RAPO3_2014_web.pdf?sequence =1. Accessed March 9, 2015. Helsinki: THL 2014